HealthEquity price target raised to $105 from $100 at RBC Capital

RBC Capital analyst Sean Dodge raised the firm’s price target on HealthEquity (HQY) to $105 from $100 and keeps an Outperform rating on the shares. The company reported a beat-and-raise Q3, with EBITDA topping estimates despite absorbing $8M of excess service costs, the analyst tells investors in a research note. HealthEquity’s initial FY26 outlook was below consensus, but the discrepancy is largely due to a combination of assumptions around specific timing of cash placements and conservatism across the board, RBC adds.